Early Responses to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration
Author Information
Author(s): Wataru Matsumiya, Shigeru Honda, Hiroaki Bessho, Sentaro Kusuhara, Yasutomo Tsukahara, Akira Negi
Primary Institution: Kobe University Graduate School of Medicine
Hypothesis
The efficacy of intravitreal ranibizumab (IVR) may differ between typical neovascular age-related macular degeneration (tAMD) and polypoidal choroidal vasculopathy (PCV).
Conclusion
The phenotype of tAMD showed a significantly better early response to IVR than PCV in terms of visual acuity improvement.
Supporting Evidence
- Patients with tAMD showed significant improvement in visual acuity at 1 and 3 months after treatment.
- PCV patients showed no significant improvement in visual acuity after treatment.
- Both tAMD and PCV groups showed significant improvements in central retinal thickness.
Takeaway
This study found that patients with a specific type of eye disease (tAMD) got better results from a treatment than those with another type (PCV).
Methodology
Sixty eyes from 60 patients were treated with three consecutive monthly IVR injections, and changes in visual acuity and retinal thickness were measured.
Potential Biases
Potential bias due to the exclusion of patients with certain prior treatments and conditions.
Limitations
The study was limited to a small sample size and only included Japanese patients.
Participant Demographics
All participants were Japanese individuals, with a mean age of approximately 74.5 years.
Statistical Information
P-Value
P = .0045
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website